Is Sunil Healthcare overvalued or undervalued?

As of 7 November 2025, the valuation grade for Sunil Healthcare has moved from attractive to fair. The company is currently fairly valued. Key ratios include a PE ratio of 44.63, an EV to EBITDA of 11.04, and a PEG ratio of 0.19. In comparison to peers, Sun Pharma has a PE ratio of 35.17 and is considered expensive, while Cipla, which is rated attractive, has a PE ratio of 22.33.
Despite the recent downgrade in valuation, Sunil Healthcare's stock has shown resilience with a 1-week return of 4.58%, outperforming the Sensex, which had a return of -0.86%. However, over the longer term, the company has underperformed, with a 1-year return of -11.93% compared to the Sensex's 4.62%. This suggests that while the company is currently fairly valued, its long-term performance may warrant further scrutiny.